LAMB3 and junctional epidermolysis bullosa: Taken together, we established a retroviral-free, dual-Cas9n gene editing strategy targeting LAMB3, with the potential to treat a large group of patients with JEB harboring the targeted hotspot variant (c.1903C>T) (Kiritsi et al, 2013).